Motley Fool co-founder and Chief Rule Breaker David Gardner presents "Battle Royale," a blood-sport investment feature in which eight stocks fight to emerge as the single best investment pick for you. Drawn at random from the top 250 most popular stocks among Fool members, and randomized again into a standard eight-team tournament bracket, the companies square off to win David's confidence as his favorite market-beater over the next 12 months. In this second-round matchup, Israeli generic-drug giant Teva Pharmaceutical
The Fool owns shares of Teva. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
Teva threw everything but the kitchen sink at its shareholders last year, but the future is beginning to look brighter.
The Big Reason Teva Pharmaceutical Industries Catapulted 28% Higher in December
Plans to "trim the fat" have Wall Street and investors excited.
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Can Valeant and Teva rebound? George Soros' namesake fund doesn't seem to think so.